TNF and amyloidosis: The reasons for switching from infliximab to another anti-TNF were ongoing underlying disease activity (n = 5), worsening of amyloidosis (n = 4), anaphylaxis (n = 4), aspergilloma (n = 1), and jugular and subclavian thrombosis (n = 1).